Terminated PHASE2 INTERVENTIONAL 2-arm NCT00441168

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade When Added to Adriamycin-Dexamethasone Treatment Versus Vincristine-Adriamycin-Dexamethasone Standard Treatment in Subjects With Multiple Myeloma Who Are Refractory to or Have Relapsed After Primary Therapy for Multiple Myeloma

Sponsor: Janssen-Cilag International NV

Conditions Multiple Myeloma

Interventions adriamycin bortezomib dexamethasone vincristine

Updated 11 times since 2017 Last updated: Feb 20, 2014 Started: Dec 31, 2006 Primary completion: Jan 31, 2008 Completion: Jan 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer be achieved

Other terminated trials from Janssen-Cilag International NV

More terminations from Janssen-Cilag International NV

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

This PHASE2 trial investigates Multiple Myeloma and is currently terminated or withdrawn. Janssen-Cilag International NV leads this study, which shows 11 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 6 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2
May 2018 — Jun 2018 [monthly]

Terminated PHASE2
Aug 2017 — May 2018 [monthly]

Terminated PHASE2
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag International NV

Data source: Janssen-Cilag International NV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ankara, Turkey (Türkiye) , Bialystok, Poland , Bursa, Turkey (Türkiye) , Debrecen, Hungary , Eskişehir, Turkey (Türkiye) , Gdansk, Poland , Kaunas, Lithuania , Klaipėda, Lithuania , Leer, Germany , Moscow, Russia and 6 more locations